Business
Boehringer, Sino Enter Cancer Drug Deal Worth Over $7 Billion
Sonja Wind·Bloomberg·November 4, 2026
Boehringer Ingelheim GmbH signed a licensing deal potentially worth more than $7 billion with China’s Sino Biopharmaceutical Limited and its subsidiaries for experimental cancer treatments.
Read the full story at Bloomberg →